WO2000038661A3 - Die verwendung von hemmern des natrium-wasserstoff-austauschers zur herstellung eines medikaments zur verhinderung von altersbedingten organ-dysfunktionen, altersbedingten erkrankungen und zur lebensverlängerung - Google Patents

Die verwendung von hemmern des natrium-wasserstoff-austauschers zur herstellung eines medikaments zur verhinderung von altersbedingten organ-dysfunktionen, altersbedingten erkrankungen und zur lebensverlängerung Download PDF

Info

Publication number
WO2000038661A3
WO2000038661A3 PCT/EP1999/009621 EP9909621W WO0038661A3 WO 2000038661 A3 WO2000038661 A3 WO 2000038661A3 EP 9909621 W EP9909621 W EP 9909621W WO 0038661 A3 WO0038661 A3 WO 0038661A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
medicament
producing
particular age
sodium hydrogen
Prior art date
Application number
PCT/EP1999/009621
Other languages
English (en)
French (fr)
Other versions
WO2000038661A2 (de
Inventor
Wolfgang Linz
Hans-Jochen Lang
Bela Kelety
Peter Schmid
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020017008052A priority Critical patent/KR20010086152A/ko
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Priority to AU16576/00A priority patent/AU776761B2/en
Priority to BR9916505-8A priority patent/BR9916505A/pt
Priority to SK904-2001A priority patent/SK9042001A3/sk
Priority to EP99959387A priority patent/EP1140056A2/de
Priority to HU0104652A priority patent/HUP0104652A3/hu
Priority to JP2000590615A priority patent/JP2002533386A/ja
Priority to IL14337299A priority patent/IL143372A0/xx
Priority to CA002357837A priority patent/CA2357837A1/en
Publication of WO2000038661A2 publication Critical patent/WO2000038661A2/de
Publication of WO2000038661A3 publication Critical patent/WO2000038661A3/de
Priority to HR20010470A priority patent/HRPK20010470B1/xx
Priority to NO20013145A priority patent/NO20013145L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Inhibitoren des zellulären Natrium-Wasserstoff-Austauschers werden zur Herstellung eines Medikaments für die Verhinderung altersbedingter Funktionsstörungen und dysfunktioneller Veränderungen von Organen des Körpers und für die Verhinderung altersbedingter Erkrankungen und für die Lebensverlängerung unter Wahrung einer verbesserten Lebensqualität verwendet. Typische Vertreter der NHE-Inhibitoren sind Cariporid (a), und Eniporid (b).
PCT/EP1999/009621 1998-12-23 1999-12-08 Die verwendung von hemmern des natrium-wasserstoff-austauschers zur herstellung eines medikaments zur verhinderung von altersbedingten organ-dysfunktionen, altersbedingten erkrankungen und zur lebensverlängerung WO2000038661A2 (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
HU0104652A HUP0104652A3 (en) 1998-12-23 1999-12-08 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life
AU16576/00A AU776761B2 (en) 1998-12-23 1999-12-08 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life
BR9916505-8A BR9916505A (pt) 1998-12-23 1999-12-08 O emprego de inibidores da troca desódio-hidrogênio para a preparação de ummedicamento para evitar disfunções de órgãoscondicionadas pela idade, doenças condicionadaspela idade e para o prolongamento da vida
SK904-2001A SK9042001A3 (en) 1998-12-23 1999-12-08 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life
EP99959387A EP1140056A2 (de) 1998-12-23 1999-12-08 Die verwendung von hemmern des natrium-wasserstoff-austauschers zur herstellung eines medikaments zur verhinderung von altersbedingten organ-dysfunktionen, altersbedingten erkrankungen und zur lebensverlängerung
KR1020017008052A KR20010086152A (ko) 1998-12-23 1999-12-08 특정의 노화 관련 기관의 기능부전과 질병 예방 및 수명연장용 약제를 제조하기 위한 나트륨 수소 교환체억제제의 용도
JP2000590615A JP2002533386A (ja) 1998-12-23 1999-12-08 年齢関連器官機能不全および年齢関連疾患予防および寿命延長のための薬剤を製造するためのナトリウム／水素交換物質阻害剤の使用
IL14337299A IL143372A0 (en) 1998-12-23 1999-12-08 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life
CA002357837A CA2357837A1 (en) 1998-12-23 1999-12-08 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life
HR20010470A HRPK20010470B1 (en) 1998-12-23 2001-06-20 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life
NO20013145A NO20013145L (no) 1998-12-23 2001-06-22 Anvendelse av inhibitorer av natriumhydrogenutbytteren for fremstilling av et medikament for prevensjon av organdysfunksjonerog -sykdommer relatert en spesiell alder og for a forlengelevetiden

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19859727A DE19859727A1 (de) 1998-12-23 1998-12-23 Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung
DE19859727.4 1998-12-23

Publications (2)

Publication Number Publication Date
WO2000038661A2 WO2000038661A2 (de) 2000-07-06
WO2000038661A3 true WO2000038661A3 (de) 2000-11-09

Family

ID=7892436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/009621 WO2000038661A2 (de) 1998-12-23 1999-12-08 Die verwendung von hemmern des natrium-wasserstoff-austauschers zur herstellung eines medikaments zur verhinderung von altersbedingten organ-dysfunktionen, altersbedingten erkrankungen und zur lebensverlängerung

Country Status (20)

Country Link
US (1) US6420430B1 (de)
EP (1) EP1140056A2 (de)
JP (1) JP2002533386A (de)
KR (1) KR20010086152A (de)
CN (1) CN1367689A (de)
AR (1) AR021965A1 (de)
AU (1) AU776761B2 (de)
BR (1) BR9916505A (de)
CA (1) CA2357837A1 (de)
CZ (1) CZ20012309A3 (de)
DE (1) DE19859727A1 (de)
HR (1) HRPK20010470B1 (de)
HU (1) HUP0104652A3 (de)
IL (1) IL143372A0 (de)
NO (1) NO20013145L (de)
RU (1) RU2238721C2 (de)
SK (1) SK9042001A3 (de)
TR (1) TR200101803T2 (de)
WO (1) WO2000038661A2 (de)
ZA (1) ZA200104301B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6844361B2 (en) * 2002-02-04 2005-01-18 Aventis Pharma Deutschland Gmbh Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
MXPA04007569A (es) * 2002-02-04 2004-11-01 Aventis Pharma Gmbh Preparacion de la combinacion del inhibidor del intercambio sodio-hidrogeno cariporida con inhibidores ace para evitar la insuficiencia cardiaca y otras disfunciones de los organos relacionadas con la edad, padecimientos relacionados con la edad y pa
US7375138B2 (en) 2002-05-18 2008-05-20 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them
FR2840302B1 (fr) * 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
US6878748B2 (en) 2002-06-13 2005-04-12 Aventis Pharma Deutschland Gmbh Fluorinated cycloalkyl-derivatized benzoylguanidines, process for their preparation, their uses as medicament, and medicament containing them
KR101153254B1 (ko) * 2003-06-26 2012-07-02 바이오트론 리미티드 항바이러스 화합물 및 방법
US8017863B2 (en) * 2005-11-02 2011-09-13 The Regents Of The University Of Michigan Polymer wrapped carbon nanotube near-infrared photoactive devices
US7947897B2 (en) * 2005-11-02 2011-05-24 The Trustees Of Princeton University Organic photovoltaic cells utilizing ultrathin sensitizing layer
US8013240B2 (en) * 2005-11-02 2011-09-06 The Trustees Of Princeton University Organic photovoltaic cells utilizing ultrathin sensitizing layer
KR101042078B1 (ko) * 2009-01-13 2011-06-16 한국항공우주산업 주식회사 치공구 제작용 수평 측면 가공 치구
CN104103253B (zh) 2014-07-04 2016-08-17 京东方科技集团股份有限公司 发射电极扫描电路、阵列基板和显示装置

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0589336A1 (de) * 1992-09-22 1994-03-30 Hoechst Aktiengesellschaft Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrythmika
EP0640587A1 (de) * 1993-08-24 1995-03-01 Hoechst Aktiengesellschaft Diacylsubstituierte Guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0699666A1 (de) * 1994-08-31 1996-03-06 MERCK PATENT GmbH Heterocyclyl-benzoylguanidine
EP0723963A1 (de) * 1995-01-28 1996-07-31 MERCK PATENT GmbH 4-Amino-benzoylguanidin-Derivate
DE19502895A1 (de) * 1995-01-31 1996-08-01 Merck Patent Gmbh 4-Mercapto-benzoylguanidin-Derivate
EP0738712A1 (de) * 1995-04-18 1996-10-23 Hoechst Aktiengesellschaft Substituierte Indenoylguanidines mit antiarrhythmischer und cardioprotektiver Wirkung
EP0765867A1 (de) * 1995-09-27 1997-04-02 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament
EP0774459A1 (de) * 1995-11-14 1997-05-21 Hoechst Aktiengesellschaft Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0810207A1 (de) * 1996-05-28 1997-12-03 Hoechst Aktiengesellschaft Bis-ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
WO1997046226A2 (de) * 1996-06-03 1997-12-11 Hoechst Aktiengesellschaft VERWENDUNG VON INHIBITOREN DES ZELLULÄREN Na+/H+-EXCHANGERS (NHE) ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR NORMALISIERUNG DER SERUMLIPIDE
DE19734693A1 (de) * 1997-08-11 1998-01-22 Hoechst Marion Roussel De Gmbh Verwendung von Cariporide als Inhibitor des zellulären NA+/H+-Exchangers (NHE) zur Herstellung eines Medikaments zur Behandlung von cardialen und nichtcardialen Krankheiten
WO1998055475A1 (en) * 1997-06-02 1998-12-10 Fujisawa Pharmaceutical Co., Ltd. Guanidine deriviatives as inhibitors of na+/h+ exchange in cells
WO1999033460A1 (en) * 1997-12-24 1999-07-08 Bristol-Myers Squibb Company Acyl guanidine sodium/proton exchange inhibitors and method
EP0937459A2 (de) * 1998-01-29 1999-08-25 Sumitomo Pharmaceuticals Company, Limited Pharmazeutische Zubereitung zur behandlung der ischämischen Gehirnkrankheit

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0590455T3 (da) * 1992-09-28 2001-01-22 Hoechst Ag Antiarrytmiske og cardioprotektive substiuerede 1(2H)-isoquinoliner, fremgangsmåde til deres fremstilling, lægemiddel indeh
SE508028C2 (sv) * 1993-05-12 1998-08-10 Moelnlycke Ab Midjebälte för absorberande plagg
DE69501219T2 (de) 1994-02-25 1998-04-16 Whitehead Alenia Sistemi Subacquei Spa Elektrolyt-aktivierte Batterie

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0589336A1 (de) * 1992-09-22 1994-03-30 Hoechst Aktiengesellschaft Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrythmika
EP0640587A1 (de) * 1993-08-24 1995-03-01 Hoechst Aktiengesellschaft Diacylsubstituierte Guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0699666A1 (de) * 1994-08-31 1996-03-06 MERCK PATENT GmbH Heterocyclyl-benzoylguanidine
EP0723963A1 (de) * 1995-01-28 1996-07-31 MERCK PATENT GmbH 4-Amino-benzoylguanidin-Derivate
DE19502895A1 (de) * 1995-01-31 1996-08-01 Merck Patent Gmbh 4-Mercapto-benzoylguanidin-Derivate
EP0738712A1 (de) * 1995-04-18 1996-10-23 Hoechst Aktiengesellschaft Substituierte Indenoylguanidines mit antiarrhythmischer und cardioprotektiver Wirkung
EP0765867A1 (de) * 1995-09-27 1997-04-02 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament
EP0774459A1 (de) * 1995-11-14 1997-05-21 Hoechst Aktiengesellschaft Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0810207A1 (de) * 1996-05-28 1997-12-03 Hoechst Aktiengesellschaft Bis-ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
WO1997046226A2 (de) * 1996-06-03 1997-12-11 Hoechst Aktiengesellschaft VERWENDUNG VON INHIBITOREN DES ZELLULÄREN Na+/H+-EXCHANGERS (NHE) ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR NORMALISIERUNG DER SERUMLIPIDE
WO1998055475A1 (en) * 1997-06-02 1998-12-10 Fujisawa Pharmaceutical Co., Ltd. Guanidine deriviatives as inhibitors of na+/h+ exchange in cells
DE19734693A1 (de) * 1997-08-11 1998-01-22 Hoechst Marion Roussel De Gmbh Verwendung von Cariporide als Inhibitor des zellulären NA+/H+-Exchangers (NHE) zur Herstellung eines Medikaments zur Behandlung von cardialen und nichtcardialen Krankheiten
WO1999033460A1 (en) * 1997-12-24 1999-07-08 Bristol-Myers Squibb Company Acyl guanidine sodium/proton exchange inhibitors and method
EP0937459A2 (de) * 1998-01-29 1999-08-25 Sumitomo Pharmaceuticals Company, Limited Pharmazeutische Zubereitung zur behandlung der ischämischen Gehirnkrankheit

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BAUMGARTH, MANFRED ET AL: "[2-Methyl-5-(methylsulfonyl)benzoyl]guanidine Na+/H+ Antiporter Inhibitors", J. MED. CHEM. (1997), 40(13), 2017-2034, XP000914594 *
BAUMGARTH, MANFRED ET AL: "Bicyclic acylguanidine Na+/H+ antiporter inhibitors", J. MED. CHEM. (1998), 41(19), 3736-3747, XP000914595 *
BEERS M.H.; BERKOW R. (EDS.).: "MERCK MANUAL OF DIAGNOSIS AND THERAPY.", 1999, MERCK & CO., INC., RAHWAY, N.J., XP002141065, 23624 *
BEIER, N. ET AL: "EMD 96785: A potent cardioprotective Na+/H+-exchange (NHE) inhibitor.", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, (JUNE, 1998) VOL. 30, NO. 6, PP. A144. MEETING INFO.: XVI WORLD CONGRESS OF THE INTERNATIONAL SOCIETY FOR HEART RESEARCH: CARDIOVASCULAR BIOLOGY AND MEDICINE INTO THE 21ST CENTURY, XP000920869 *
BERKOW R.; FLETCHER A. (EDS.).: "MERCK MANUAL OF DIAGNOSIS AND THERAPY.", 1987, MERCK & CO., INC., RAHWAY, N.J., XP002141064, 14658 *
GRAUL, A. ET AL: "Cariporide Mesilate. Cardioprotectant Na+/H+-exchange inhibitor", DRUGS FUTURE (1997), 22(11), 1197-1200, XP000920592 *
GUMINA, RICHARD J. ET AL: "A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion", J. PHARMACOL. EXP. THER. (1998), 286(1), 175-183, XP000920539 *
HILDEBRANDT H. (ED.).: "PSCHYREMBEL KLINISCHES WOERTERBUCH", 1998, WALTER DE GRUYTER, BERLIN NEW YORK, XP002141063, 240171 *
HOQUE, A.N. EHSANUL ET AL: "Effect of sodium-hydrogen exchange inhibition on functional and metabolic impairment produced by oxidative stress in the isolated rat heart", CAN. J. PHYSIOL. PHARMACOL. (1997), 75(4), 326-334, XP000920595 *
LEVITSKY, JOSH ET AL: "Sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury", J. CLIN. PHARMACOL. (1998), 38(10), 887-897, XP000920868 *
LINZ, W. ET AL: "Dose-dependent reduction of myocardial infarct mass in rabbits by the NHE-1 inhibitor cariporide ( HOE 642 )", CLIN. EXP. HYPERTENS. (1998), 20(7), 733-749, XP000920536 *
MIURA, TETSUJI ET AL: "Infarct size limitation by a new Na+-H+ exchange inhibitor, Hoe 642: difference from preconditioning in the role of protein kinase C", J. AM. COLL. CARDIOL. (1997), 29(3), 693-701, XP000920593 *
MYERS, MARY LEE ET AL: "Hydrogen peroxide-induced impairment of post-ischemic ventricular function is prevented by the sodium-hydrogen exchange inhibitor HOE 642 ( cariporide )", CARDIOVASC. RES. (1998), 40(2), 290-296, XP000920530 *
PFEFFER M A; FINN P V; GANNON J B; PFEFFER J M: "Cariporide, a Na+/H+ ion exchange inhibitor, prolongs survival in rats with experimental myocardial infarction.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 31, 1998, pages 268a, XP002141068 *
SCHOLZ W ET AL: "PROTECTIVE EFFECTS OF HOE642, A SELECTIVE SODIUM-HYDROGEN EXCHANGE SUBTYPE 1 INHIBITOR, ON CARDIAC ISCHAEMIA AND REPERFUSION", CARDIOVASCULAR RESEARCH,XX,XX, vol. 29, no. 2, 1 January 1995 (1995-01-01), pages 260 - 268, XP000602918, ISSN: 0008-6363 *

Also Published As

Publication number Publication date
WO2000038661A2 (de) 2000-07-06
TR200101803T2 (tr) 2001-10-22
AU1657600A (en) 2000-07-31
CA2357837A1 (en) 2000-07-06
EP1140056A2 (de) 2001-10-10
RU2001120358A (ru) 2005-12-10
SK9042001A3 (en) 2001-12-03
AR021965A1 (es) 2002-09-04
IL143372A0 (en) 2002-04-21
CZ20012309A3 (cs) 2001-09-12
CN1367689A (zh) 2002-09-04
ZA200104301B (en) 2003-02-20
HRP20010470A2 (en) 2002-06-30
AU776761B2 (en) 2004-09-23
HUP0104652A3 (en) 2002-09-30
BR9916505A (pt) 2001-11-20
HRPK20010470B1 (en) 2003-10-31
RU2238721C2 (ru) 2004-10-27
US6420430B1 (en) 2002-07-16
KR20010086152A (ko) 2001-09-08
NO20013145L (no) 2001-08-22
JP2002533386A (ja) 2002-10-08
HUP0104652A2 (hu) 2002-03-28
NO20013145D0 (no) 2001-06-22
DE19859727A1 (de) 2000-06-29

Similar Documents

Publication Publication Date Title
WO2000038661A3 (de) Die verwendung von hemmern des natrium-wasserstoff-austauschers zur herstellung eines medikaments zur verhinderung von altersbedingten organ-dysfunktionen, altersbedingten erkrankungen und zur lebensverlängerung
MXPA03005893A (es) Proteccion, restauracion, y mejora de celulas, tejidos y organos que responden a la eritropoyetina.
NO20015279L (no) Legeme for å tilveiebringe innvekst og vekst av benvev og/eller bindevev og fremgangsmåte for fremstilling av et sliktlegeme
ATE512095T1 (de) Zigarettenpackung
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
HK1047887B (zh) 氨基酸的四氫噻唑-或四氫化吡咯衍生物作為抗高血糖劑的應用
CA2198603A1 (en) Use of Stem Cell Factor and Soluble Interleukin-6 Receptor for the Ex Vivo Expansion of Hematopoietic Multipotential Cells
BG103413A (en) Derivatives of sulphinic acid, their production and application
CA2245142A1 (en) New phenanthridines
NO20001583L (no) Stimulering av hematopoetiske celler in vitro
CA2420694A1 (en) Guanidinobenzamides as mc4-r agonists
BR0106506A (pt) Método e sistema de individualização de calibração de curvas de reprodução de tons e sua aplicação
IL148680A0 (en) Architecture, method(s) and circuitry for low power memories
NO973701L (no) Piezoelektrisk lydgiver i miniatyrutförelse
ATE293841T1 (de) Entladungslampe für dielektrisch behinderte entladungen mit verbesserter elektrodenkonfiguration
NZ500992A (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
AU2830601A (en) Substrate-protected electrode-electrolyte unit
ZA200200340B (en) Storage of microorganisms, cells and tissue.
MX9700624A (es) Azolidinonas de imidazopiridina.
TNSN86166A1 (fr) Fongicides a groupes triazole et oligoether et associations
MX9700854A (es) Derivados de azabicicloheptano n-substituidos utiles como neurolepticos.
DE50312695D1 (de) Bipolare platte für eine brennstoffzelle
AU4944899A (en) New pharmaceutically active compounds
KR970702880A (ko) 신규한 펩티드 활성 물질 및 그의 제조 방법(New Peptide Active Substance And Production Thereof)
WO2002076383A3 (en) Securin is required for chromosomal stability in human cells

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99815044.4

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2000 16576

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/004956

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 143372

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2001/04301

Country of ref document: ZA

Ref document number: 200104301

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1999959387

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PK20010470A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: PV2001-2309

Country of ref document: CZ

Ref document number: 512529

Country of ref document: NZ

Ref document number: 9042001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2000 590615

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017008052

Country of ref document: KR

Ref document number: 16576/00

Country of ref document: AU

Ref document number: 2001/01803

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2357837

Country of ref document: CA

Ref document number: 2357837

Country of ref document: CA

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020017008052

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-2309

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1999959387

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 16576/00

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1999959387

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999959387

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2001-2309

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1020017008052

Country of ref document: KR